SEC Form 4 filed by Stereotaxis Inc.
$STXS
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Unavailable
Get the next $STXS alert in real time by email
Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $STXS
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/10/2024 | $5.00 | Buy | ROTH MKM |
| 7/12/2022 | $6.00 | Buy | Aegis Capital |
| 6/23/2022 | $6.00 | Buy | B. Riley Securities |
| 1/5/2022 | $11.00 | Buy | Craig-Hallum |
| 1/5/2022 | $13.00 | Buy | Loop Capital |
Stereotaxis Highlighted by NVIDIA at GTC Artificial Intelligence Conference and Accepted into NVIDIA Connect Program
ST. LOUIS, March 19, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that NVIDIA highlighted Stereotaxis' technology at NVIDIA GTC and has accepted Stereotaxis into the NVIDIA Connect program. NVIDIA GTC (GPU Technology Conference) is a global artificial intelligence (AI) conference that brings together engineers, researchers, and inventors working to pioneer applications for AI. This year's conference has brought together over 25,000 attendees in San Jose this week. At a special address by NVIDIA's Vice President of Healthcare and Life Sciences, NVIDIA highlighted Ster
Stereotaxis to Present at 37th Annual Roth Conference
ST. LOUIS, March 10, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will participate in the 37th Annual ROTH Conference in Dana Point, California. Mr. Fischel will be available for one-on-one meetings on Monday, March 17th, 2025. "We appreciate the opportunity to participate in the Roth Conference and to share Stereotaxis' differentiated technology and growth strategy with the investment community," says Mr. Fischel. About StereotaxisStereotaxis (NYSE:STXS) is a pioneer and global leader in innovative surgical robotics for minimally
Stereotaxis Submits EMAGIN Catheter for Regulatory Clearance as it Pioneers Robotics for Endovascular Surgery
ST. LOUIS, March 03, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced FDA regulatory submission for the first robotically navigated catheter designed to expand usage of Robotic Magnetic Navigation into the broader endovascular field. EMAGIN™ 5F is the first in a family of robotically navigated endovascular devices being developed by Stereotaxis. The EMAGIN brand – short for Endovascular Magnetic Intervention – will encompass a comprehensive portfolio of robotic catheters and wires. EMAGIN 5F is a catheter guide with a 5-French diameter used to navigate tortuous venous and ar
ROTH MKM initiated coverage on Stereotaxis with a new price target
ROTH MKM initiated coverage of Stereotaxis with a rating of Buy and set a new price target of $5.00
Aegis Capital initiated coverage on Stereotaxis with a new price target
Aegis Capital initiated coverage of Stereotaxis with a rating of Buy and set a new price target of $6.00
B. Riley Securities initiated coverage on Stereotaxis with a new price target
B. Riley Securities initiated coverage of Stereotaxis with a rating of Buy and set a new price target of $6.00
Director Isaac Paul J bought $68,780 worth of shares (38,000 units at $1.81), increasing direct ownership by 77% to 87,299 units (SEC Form 4)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
Director Isaac Paul J bought $44,836 worth of shares (24,788 units at $1.81), increasing direct ownership by 90% to 49,066 units (SEC Form 4)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
Director Isaac Paul J bought $15,350 worth of shares (8,095 units at $1.90) (SEC Form 4)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
Director Isaac Paul J bought $68,780 worth of shares (38,000 units at $1.81), increasing direct ownership by 77% to 87,299 units (SEC Form 4)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
Director Isaac Paul J bought $44,836 worth of shares (24,788 units at $1.81), increasing direct ownership by 90% to 49,066 units (SEC Form 4)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
Director Menawat Arun Swarup was granted 56,497 shares, increasing direct ownership by 7% to 901,841 units (SEC Form 4)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
SEC Form DEFA14A filed by Stereotaxis Inc.
DEFA14A - Stereotaxis, Inc. (0001289340) (Filer)
SEC Form DEF 14A filed by Stereotaxis Inc.
DEF 14A - Stereotaxis, Inc. (0001289340) (Filer)
SEC Form 10-K filed by Stereotaxis Inc.
10-K - Stereotaxis, Inc. (0001289340) (Filer)
Stereotaxis Technology to be Featured at Annual Meeting of the Society for Cardiac Robotic Navigation
ST. LOUIS, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will participate in the Society for Cardiac Robotic Navigation's Annual Meeting taking place October 28-29 in Lisbon, Portugal. The global physician-led Society for Cardiac Robotic Navigation (SCRN) is dedicated to establishing a community and platform for users of robotic technologies in cardiology. The annual SCRN conference provides a venue for physicians and healthcare professionals to share best practices, discuss new clinical literature, and evaluate the latest innovations in technology. The
Stereotaxis Strengthens Board of Directors with Appointment of Nachum Shamir
ST. LOUIS, July 18, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced the appointment of Nachum "Homi" Shamir to its Board of Directors. Mr. Shamir most recently served as Chairman and Chief Executive Officer of Luminex Corporation from 2014 through its sale to DiaSorin S.p.A. for $1.8 Billion in 2021. Prior to Luminex, Mr. Shamir served as President and Chief Executive Officer of Given Imaging from 2006 through its sale to Covidien for $1 Billion in 2014. He currently serves as Chairman of Mediwound, a publicly-traded leader in enzymatic therapeutics for burn and wound-care, and SSI Diagnosti
Stereotaxis Strengthens Board of Directors with Appointment of Myriam J. Curet, M.D.
ST. LOUIS, July 26, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the appointment of Myriam J. Curet, M.D., to its Board of Directors. Dr. Curet currently serves as Executive Vice President and Chief Medical Officer for Intuitive Surgical, the global leader and pioneer of robotic surgery. Dr. Curet joined Intuitive Surgical in 2005 and has since led the development of clinical evidence, physician education, and reimbursement and regulatory activities that have been instrumental to Intuitive Surgical's growth across multiple clinical specialties. For more than 20 years, Dr. Cu
Stereotaxis Reports 2024 Full Year Financial Results
ST. LOUIS, March 03, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2024. "We have started a milestone rich year in which we will demonstrate the tangible reality of our overall strategic transformation into a company with an easily adopted robot that can navigate a proprietary set of catheters in EP and broadly across endovascular procedures," said David Fischel, Chairman and CEO. "Our progress leads to an expanded clinical impact, scalable capital model, strategic self-sufficiency, and an attractiv
Stereotaxis to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
ST. LOUIS, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2024 fourth quarter and full year on Monday, March 3, 2025 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 8:30 a.m. ET that day to discuss the Company's results and corporate developments. What:Stereotaxis fourth quarter and full year 2024 financial results conference call When:Monday, March 3, 2025 at 8:30 a.m. ET (5:30 a.m. PT) Dial In Number:To access the live call, dial 800-715-9871 (US and Canada) or
Stereotaxis Reports 2024 Third Quarter Financial Results
ST. LOUIS, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2024. "The past quarter was marked by solid commercial execution, continued broad-based technological progress, successful operational integration of APT, and maintained financial discipline," said David Fischel, Chairman and CEO. "We are making broad, methodical progress in establishing the healthy foundations for a preeminent robotic surgery company." "Revenue growth in the third quarter was driven by continued demand for Genesis with par
SEC Form SC 13G/A filed by Stereotaxis Inc. (Amendment)
SC 13G/A - Stereotaxis, Inc. (0001289340) (Subject)
SEC Form SC 13G/A filed by Stereotaxis Inc. (Amendment)
SC 13G/A - Stereotaxis, Inc. (0001289340) (Subject)
SEC Form SC 13G/A filed by Stereotaxis Inc. (Amendment)
SC 13G/A - Stereotaxis, Inc. (0001289340) (Subject)